Rankings
▼
Calendar
ALKS Q1 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena
ALKS
Alkermes plc
$5B
Q1 2021 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$251M
+2.1% YoY
Gross Profit
$210M
83.7% margin
Operating Income
-$16M
-6.5% margin
Net Income
-$22M
-8.9% margin
EPS (Diluted)
$-0.14
QoQ Revenue Growth
-10.2%
Cash Flow
Operating Cash Flow
-$45M
Free Cash Flow
-$53M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$1.9B
Total Liabilities
$827M
Stockholders' Equity
$1.1B
Cash & Equivalents
$205M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$251M
$246M
+2.1%
Gross Profit
$210M
$199M
+5.7%
Operating Income
-$16M
-$37M
+56.0%
Net Income
-$22M
-$39M
+42.0%
Revenue Segments
Product
$130M
50%
Vivitrol
$75M
29%
Aristada And Aristada Initio
$55M
21%
← FY 2021
All Quarters
Q2 2021 →